Orforglipron: An oral GLP-1, which showed results of -16% in major adverse cardiovascular event (MACE-4) risk and -23% in MACE-3 risk in type 2 diabetes patients in the Phase 3 trial ATTAIN-4
Enhancing GSH, mainly through NAC, GSH precursors or pro-GSH compound administration, becomes a potential treatment option for SARS-CoV-2 infection and COVID-19 disease by reducing oxidative stress and cytokine expression especially in diabetic patients at risk of more severe disease (Singh et al., 2022)
A prescription does not provide essential education or guidance needed to make lasting lifestyle adjustments
Carmen Chai Author Carmen Chai is a Canadian journalist and award-winning health reporter
Oral glutathione is largely broken down by stomach acids, resulting in poor absorption
Emerging concerns include: Risks of micronutrient deficiencies caused by very low food intake